ArticleScientific reports2016
Engineering Salmonella as intracellular factory for effective killing of tumour cells.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 74 citations in OpenAlex.
- Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems.Advanced drug delivery reviews · 2026Review
- Engineered bacteria launch and control an oncolytic virus.Nature biomedical engineering · 2026Article
- The multi-kingdom cancer microbiome.Nature microbiology · 2025Review
- Advances in the Relationship Between Skin Tumor Occurrence, Development, Prognosis, and the Human Microbiome.Current microbiology · 2025Review
- Mathematical Modeling ofBioengineering (Basel, Switzerland) · 2025Article
- Designing live bacterial therapeutics for cancer.Advanced drug delivery reviews · 2025Review
- Tumor microbiome: roles in tumor initiation, progression, and therapy.Molecular biomedicine · 2025Review
- Controlling intracellular protein delivery, tumor colonization and tissue distribution using flhDC in clinically relevant ΔsseJ Salmonella.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Oncolytic bacteria: A revolutionary approach to cancer therapy.Open life sciences · 2025Review
- Spirulina Unveiled: A Comprehensive Review on Biotechnological Innovations, Nutritional Proficiency, and Clinical Implications.Current pharmaceutical biotechnology · 2025Review
- Veillonella parvula as an anaerobic lactate-fermenting bacterium for inhibition of tumor growth and metastasis through tumor-specific colonization and decrease of tumor's lactate level.Scientific reports · 2024Article
- Next-Generation Probiotics as Novel Therapeutics for Improving Human Health: Current Trends and Future Perspectives.Microorganisms · 2024Review
- Genetically Engineered Microorganisms and Their Impact on Human Health.International journal of clinical practice · 2024Review
- Microscope Subcellular Localization of Plant-Interacting Bacterial Effectors in Animal Cell Cultures.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Multitask Approach to Localize Rhizobial Type Three Secretion System Effector Proteins Inside Eukaryotic Cells.Plants (Basel, Switzerland) · 2023Article
- Modes of therapeutic delivery in synthetic microbiology.Trends in microbiology · 2023Review
- Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy.Signal transduction and targeted therapy · 2023Review
- Review
- Engineering bacteria as interactive cancer therapies.Science (New York, N.Y.) · 2022Review
- Safety assessment of compliant, highly invasive, lipid A-altered, O-antigen-defected Salmonella strains as prospective vaccine delivery systems.Veterinary research · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salmonella have many desirable properties as antitumour-agent due to its ability to proliferate inside tumours and induce tumour regression. Additionally, this bacterium can be genetically engineered to deliver therapeutic proteins intratumourally. The main limitation of this approach is the efficient release of therapeutic molecules from intratumoural bacteria. Here we have developed an inducible autolysis system based in the lysis operon of the lambda phage that, in response to anhydrotetracycline, lysates Salmonella thus releasing its content. The system was combined with a salicylate cascade system that allows efficient production of therapeutic molecules in response to aspirin and with a sifA mutation that liberates bacteria from the vacuoles to a cytosolic location. The combination of these three elements makes this strain a putative powerful instrument in cancer treatment. We have used this engineered strain for the intracellular production and delivery of Cp53 peptide. The engineered strain is able to sequentially produce and release the cytotoxic peptide while proliferating inside tumour cells, thus inducing host cell death. Our results show that temporal separation of protein production from protein release is essential to efficiently kill tumour cells. The combined system is a further step in the engineering of more efficient bacteria for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.